Welcome to our dedicated page for cbli news (Ticker: cbli), a resource for investors and traders seeking the latest updates and insights on cbli stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect cbli's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of cbli's position in the market.
Cytocom, Inc. (Nasdaq: CBLI) will change its corporate name to Statera BioPharma, Inc. and update its ticker symbol to STAB, effective September 1, 2021. This change reflects the company’s strategic focus on immune restoration and addressing autoimmune diseases, cancer, and other health conditions. Following a merger on July 27, 2021, Statera BioPharma aims to advance its late-stage clinical assets, emphasizing its lineage in immune modulation. A new logo and website will accompany this rebranding.
Cytocom, Inc. (NASDAQ: CBLI) announced the availability of the audio archive for their second quarter 2021 financial results conference call, accessible on their website for 90 days starting August 16, 2021. Cytocom focuses on developing innovative immunotherapies targeting various conditions including autoimmune disorders, neutropenia, emerging viruses, and cancers. Their proprietary platform aims to rebalance the immune system. The company is currently involved in multiple clinical development programs for conditions such as Crohn's disease and COVID-19.
Cytocom, Inc. (Nasdaq: CBLI) reported its second-quarter financial results for 2021, revealing no revenue compared to $0.06 million in Q2 2020. The net loss increased to $(0.7) million, or $(0.04) per share, attributed to reduced income and higher administrative costs. Following a merger in July 2021, Cytocom has secured $90 million in financing to enhance its pipeline of eight drug candidates across 21 indications, including trials for pediatric Crohn's disease and COVID-19. The company expects strong growth and aims to start patient enrollment in several clinical trials by mid-2022.
Cytocom, Inc. (NASDAQ: CBLI) has announced a collaboration with the La Jolla Institute for Immunology to fund research over a five-year period. This partnership aims to develop immune-modulating agents targeting toll-like receptors for cancer, infectious diseases, and autoimmune conditions. Cytocom will provide up to $1.4 million annually for research projects and also gain rights to negotiate licenses for new discoveries. This agreement follows the merger with Cleveland BioLabs and supports Cytocom's goal of advancing innovative immune therapies.
Cytocom, a clinical-stage biopharmaceutical company (NASDAQ: CBLI), announced its participation in the Empowering the Kingdom through Business Conference at Liberty University from August 10-12, 2021. CEO Mike K. Handley will be a featured panelist in the Healthcare Breakout session on August 11. The company focuses on developing innovative immune therapies targeting autoimmune disorders and cancers, leveraging a proprietary platform for immune restoration. Cytocom is currently advancing multiple clinical-stage programs, including treatments for Crohn's disease and pancreatic cancer.
Cytocom, Inc. (NASDAQ: CBLI) will host a conference call on August 16, 2021, at 8:30 a.m. ET, to discuss its Q2 2021 financial results. The event will be accessible via a live audio webcast and telephone, with details provided. The company is focused on developing novel immunotherapies targeting autoimmune diseases, cancers, and emerging viruses. Cytocom leverages a proprietary platform to restore immune balance. Updates on their clinical-stage programs will be discussed, including initiatives for Crohn's disease and COVID-19.
Cytocom Inc. (NASDAQ: CBLI) updated investors on its clinical programs, focusing on immune therapies for diverse conditions, including Crohn's disease and cancer. The company plans to enroll patients by the end of 2021 for a Phase 3 trial of its lead candidate CYTO-201. Additionally, Cytocom aims to explore new indications for entolimod and develop CYTO-401 for pancreatic cancer. The firm is also preparing trials for CYTO-205 targeting COVID-19 and post-acute symptoms. While the management displays optimism, the success of these programs remains uncertain amid industry challenges.
Cytocom Inc. (NASDAQ: CBLI) has successfully completed its merger with Cleveland BioLabs as of July 27, 2021. This all-stock transaction, initially announced in October 2020, positions Cytocom to enhance its clinical programs and expand its immunotherapy platforms. The company's President, Michael K. Handley, expressed optimism about achieving key financial and developmental milestones in the next 12-18 months. Additionally, Cytocom acquired ImQuest Life Sciences, contributing to the company’s robust immunotherapy pipeline valued at $12 million. Shareholders will receive further updates soon.
Cytocom, Inc. (NASDAQ: CBLI) has secured $90 million in committed capital, spearheaded by a $75 million equity commitment from GEM Global Yield LLC SCS. Following a recent merger with Cleveland BioLabs, the company plans to draw $15 million within 30 days and access an additional $17 million from Avenue Capital and Adit Ventures. The funds will support operations, growth initiatives, and further clinical development of their pipeline targeting diseases like COVID-19 and cancer.
Cleveland BioLabs (NASDAQ: CBLI) and Cytocom, Inc. announced an investor call on July 7, 2021, to discuss the results of the merger vote held on July 6, 2021. The call will include insights from CEO Michael K. Handley and Cleveland BioLabs' Board members, focusing on the strategic vision for the merged company. The combined entity aims to target significant markets, including the $48.7 billion gastrointestinal market, the $84.3 billion oncology market, and the $125 billion autoimmune market. This merger may enhance the development of therapies for various immune-related diseases.
